Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis

AbstractObjectiveTo discuss the application of ARMS method to detect EGFR gene mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis.Methods5 cases of lung adenocarcinoma were identified with meningeal metastasis that were cleared EGFR gene mutation by gene sequencing method. From each patient 5ml cerebrospinal fluid was obtained by lumbar puncture. ARMS method was used to detect EGFR mutations in cerebrospinal fluid.Results5 samples of cerebrospinal fluid were successfully detected by ARMS method, 3 samples found that EGFR gene mutations, the mutations in line with direct sequencing method.ConclusionARMS method can be used to detect EGFR gene mutations of cerebrospinal fluid samples in lung adenocarcinoma with meningeal metastasis. But cerebrospinal fluid specimens from histological specimens, blood samples need to be confirmed by further comparative study whether there is advantage.

Download Full-text

EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma

OncoTargets and Therapy ◽

10.2147/ott.s87146 ◽

2015 ◽

pp. 3017 ◽

Cited By ~ 5

Author(s):

Yaoyao Ren ◽

Yibing Yao ◽

Qing Ma ◽

Diansheng Zhong

Keyword(s):

Decision Making ◽

Lung Adenocarcinoma ◽

Gene Mutation ◽

Therapeutic Decision ◽

Mutation Status ◽

Egfr Gene ◽

Therapeutic Decision Making ◽

Egfr Gene Mutation

Download Full-text

LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation

10.1183/13993003.congress-2016.pa2880 ◽

2016 ◽

Author(s):

Marisol Arroyo Hernandez ◽

Alexander J. Alatorre ◽

Julio C. Garibay ◽

José F. Escobar ◽

Jerónimo Rodríguez

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Treatment Efficacy ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

A Case of EGFR Gene Mutation-positive Early Lung Adenocarcinoma That Recurred 12 Years Postoperatively with Meningeal Carcinomatosis Alone

Haigan ◽

10.2482/haigan.60.192 ◽

2020 ◽

Vol 60 (3) ◽

pp. 192-196

Author(s):

Keiichi Nakamura ◽

Yuka Fujita ◽

Chie Mori ◽

Hokuto Suzuki ◽

Hikaru Kuroda ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Meningeal Carcinomatosis ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.7574 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 7574-7574 ◽

Cited By ~ 9

Author(s):

T. Kosaka ◽

Y. Yatabe ◽

R. Onozato ◽

T. Mitsudomi

Keyword(s):

Lung Adenocarcinoma ◽

Early Stage ◽

Gene Mutations ◽

Egfr Mutations ◽

Prognostic Impact ◽

Egfr Gene ◽

Deletion Mutations ◽

Exon 19 Deletion ◽

Never Smokers ◽

Exon 19

7574 Background: Prognostic impact of epidermal growth factor receptor (EGFR) gene mutations in lung adenocarcinoma remains controversial. We examined a large cohort of lung adenocarcinoma resected in a single institution for EGFR mutations and evaluated its prognostic implication. Methods: We analyzed 402 patients with lung adenocarcinoma who underwent potentially curative pulmonary resection at our department, from May 2000 through December 2005. Total RNA was extracted and direct sequencing of exons 18–21 of EGFR gene was performed after reverse transcription - polymerase chain reaction. KRAS and TP53 gene mutations were also analyzed in 209 adenocarcinoma patients from this cohort. Results: We found that 196 patients (49%) had EGFR mutations. Of them, exon 19 deletion mutations were 83 (42%) and L858R mutations were 92 (47%). EGFR mutations were significantly frequent in female (P<0.0001), never smokers (P<0.0001), and well to moderately differentiated adenocarcinoma (P<0.0001). In 347 patients who were not treated with gefitinib, prognostic effect of EGFR mutations was evaluated. Patients with EGFR mutations survived for a longer period than those without the mutations after surgery in univariate analysis (P=0.0046, log rank test). We did not detect any difference in overall survival between the patients with exon 19 deletion mutations and those with L858R mutations (P=0.3962). There were tendencies that patients with KRAS mutations or TP53 mutations survived for a shorter period than those without mutations, although there was no statistical significance (P=0.2534 and 0.0859). Multivariate analysis using the Cox proportional hazards model revealed that never smokers (P=0.0253) and disease stage (P<0.0001) were independent prognostic factors. However, all gene mutations were not independent prognostic factors (EGFR; P=0.4763, KRAS; P=0.7998, TP53; P=0.3464). Conclusion: EGFR mutations were not independently associated with prognosis of patients with early stage adenocarcinoma of the lung. Furthermore, there was no difference between exon 19 deletion mutations and L858R mutations in their prognostic impact. No significant financial relationships to disclose.

Download Full-text

The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e15629 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e15629-e15629 ◽

Cited By ~ 1

Author(s):

M. Ueno ◽

S. Ohkawa ◽

Y. Sakamoto ◽

K. Miyakawa ◽

Y. Miyagi

Keyword(s):

Lung Cancer ◽

Pancreatic Cancer ◽

Cancer Patients ◽

Direct Sequencing ◽

Advanced Pancreatic Cancer ◽

Phase Iii ◽

Egfr Mutations ◽

Egfr Expression ◽

Sequencing Method ◽

Direct Sequencing Method

e15629 Background: The standard chemotherapy of advanced pancreatic cancer is still gemcitabine and recently gemcitabine + EGFR tyrosine kinase inhibitor (TKI)is noted to be positive on Phase III study. In lung cancer, EGFR mutations (the deletion of exon 19, the point mutation of exon 18, 21) have been reported to be correlated with the effect of EGFR TKI. On the other hand, such EGFR mutations were not reported to be recognized by the direct sequencing method in pancreatic cancer. This time we examined EGFR expressions and EGFR mutations in advanced pancreatic cancer. Methods: We examined EGFR expressions immunohistochemically and EGFR mutations by Loop-Hybrid Mobility Shift Assay (LH-MSA) which is more sensitive than the direct sequencing method in the tissue obtained from percutaneous biopsies in advanced pancreatic cancer patients. In addition we examined the correlation between EGFR expressions and survivals by the log-rank test. Results: The subjects were 31 inoperable pancreatic cancer patients. Patients received chemotherapy (gemcitabine: 10, S-1: 8, gemcitabine+S-1: 12, no treatment: 1).The UICC stages were as follows:stage II; 2, stage III; 6, stage IV; 23. The tissues were obtaind from liver; 12, pancreas; 19. EGFR expressions were positive; 15, negative; 16. EGFR expressions were not correlated with survival (p=0.386). Although LH-MSA were performed successfully in all patients, the same EGFR mutations as lung cancer were not detected. Conclusions: EGFR expressions were not correlated with survivals and the same EGFR mutations as lung cancer were not detected in inoperable advanced pancreatic cancer. No significant financial relationships to disclose.

Download Full-text

The value of Fn14, CD44v, and EGFR expression in lung adenocarcinoma patients with and without activating EGFR gene mutation.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e20514 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e20514-e20514

Author(s):

Maciej Bryl ◽

Katarzyna Bednarek-Rajewska ◽

Przemysław Zalewski ◽

Małgorzata Janicka-Jedyńska ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Prognostic Value ◽

Neoplastic Disease ◽

Study Group ◽

Secondary Resistance ◽

Egfr Gene ◽

Egfr Expression ◽

Nsclc Patients ◽

Egfr Gene Mutation

e20514 Background: Lung cancer is considered the most common cause of death in the world. The prognosis for patients is poor and depends on the clinical stage and the histological type of cancer. There is a need to identify and develop new therapeutic targets that could improve the prognosis of NSCLC patients and may be responsible for development of resistance to TKI therapy. Increased expression of Fn14 or CD44v and EGFR was observed in many tumors and also correlated with the overall survival of NSCLC patients Methods: We analyzed the clinical data and the immunohistochemical expression of Fn14, CD44v and EGFR in tumor tissues from 61 patients with NSCLC divided in two groups according to the presence of activating EGFR gene mutation. The aim of the study was to evaluate the correlation between the expression of the studied molecules and the neoplastic disease course of NSCLC patients. Results: Increased expression of Fn14 was observed in study group (B) compared to expression of this molecule in the control group (K). There were no differences in the intensity of the reaction with anti CD44v and EGFR antibodies in both groups. OS was significantly longer in the study group. Histological grade of tumor correlated with the intensity of CD44v expression in both groups. There was no correlation between the OS and Fn14 expression in any group. Negative correlation was noted between the expression of CD44v and the OS in the study group and between EGFR expression and the OS in both groups. Conclusions: Our observations suggest that the expression of CD44v and EGFR may be useful clinical markers of prognostic value in lung adenocarcinoma patients regardless of the presence of activating mutation in EGFR gene. Simultaneous assessment of Cd44v and EGFR expression may grant a greater prognostic value than the assessment of each receptor separately. Increased expression of Fn14 receptor in patients with EGFR gene mutation may become a new target in therapy allowing to eliminate the problem of secondary resistance to treatment with TKI’s

Download Full-text

P3.16-013 Prognostic Effect of EGFR Gene Mutation for Recurrence in Completely Resected Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1819 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2348

Author(s):

I.K. Park ◽

K. Hyun ◽

S. Park ◽

C.H. Kang ◽

Y. Kim

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Egfr Gene ◽

Prognostic Effect ◽

Egfr Gene Mutation

Download Full-text

Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation.

Problems in oncology ◽

10.37469/0507-3758-2021-67-2-246-253 ◽

2021 ◽

Vol 67 (2) ◽

pp. 246-253

Author(s):

Konstantin Laktionov ◽

Denis Yudin ◽

Yuliya Maevskaya ◽

Lyubov` Vladimirova ◽

Dimitr Marinov ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Gene Mutation ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Mutations ◽

Genetic Profile ◽

Tumor Resistance ◽

Egfr Gene ◽

Egfr Gene Mutation

The EGFR gene mutation occurs in 15% of patients with NSCLC. Tumors with such a molecular genetic profile are characterized by high sensitivity to therapy with EGFR tyrosine kinase inhibitors. However, the majority of EGFRm+ patients develop resistance to 1-2 generation TKI therapy after 9-13 months. In our study, we considered an integrated regimen combined use chemotherapy and targeted therapy as a possible way to overcome acquired tumor resistance to TKIs of 1–2 generations. The study included patients with IIIB / IV stages of NSCLC with activating EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were administrated at days 71-113. Thereafter, gefitinib was re-started on day 135 and continued until disease progression. The median PFS was 20.- months (16.0-23.9 months, CI 95%). One -year progression-free survival (PFS) in patients who completed the chemotherapy stage was 79,6 %, two-year PFS - 38,9%. Brain metastases among patients with a progression of the disease were observed in 12 people (28.6%). The data obtained confirm the promise of using integrated chemotherapy with TKIs as a way to overcome the development of acquired resistance to TKIs of 1–2 generations.

Download Full-text